Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression.

Roghanian A, Hu G, Fraser C, Singh M, Foxall RB, Meyer MJ, Lees E, Huet H, Glennie MJ, Beers SA, Lim SH, Ashton-Key M, Thirdborough SM, Cragg M, Chen J.

Cancer Immunol Res. 2019 Aug 26. pii: canimm.0835.2018. doi: 10.1158/2326-6066.CIR-18-0835. [Epub ahead of print]

PMID:
31451483
2.

New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcγRIIB (CD32B).

Roghanian A, Stopforth RJ, Dahal LN, Cragg MS.

J Leukoc Biol. 2018 Feb 6. doi: 10.1002/JLB.2MIR0917-354R. [Epub ahead of print] Review.

PMID:
29406570
3.

Corrigendum: In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis.

Roper J, Tammela T, Cetinbas NM, Akkad A, Roghanian A, Rickelt S, Almeqdadi M, Wu K, Oberli MA, Sánchez-Rivera F, Park YK, Liang X, Eng G, Taylor MS, Azimi R, Kedrin D, Neupane R, Beyaz S, Sicinska ET, Suarez Y, Yoo J, Chen L, Zukerberg L, Katajisto P, Deshpande V, Bass AJ, Tsichlis PN, Lees J, Langer R, Hynes RO, Chen J, Bhutkar A, Jacks T, Yilmaz ÖH.

Nat Biotechnol. 2017 Dec 8;35(12):1211. doi: 10.1038/nbt1217-1211a.

PMID:
29220013
4.

In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis.

Roper J, Tammela T, Cetinbas NM, Akkad A, Roghanian A, Rickelt S, Almeqdadi M, Wu K, Oberli MA, Sánchez-Rivera FJ, Park YK, Liang X, Eng G, Taylor MS, Azimi R, Kedrin D, Neupane R, Beyaz S, Sicinska ET, Suarez Y, Yoo J, Chen L, Zukerberg L, Katajisto P, Deshpande V, Bass AJ, Tsichlis PN, Lees J, Langer R, Hynes RO, Chen J, Bhutkar A, Jacks T, Yilmaz ÖH.

Nat Biotechnol. 2017 Jun;35(6):569-576. doi: 10.1038/nbt.3836. Epub 2017 May 1. Erratum in: Nat Biotechnol. 2017 Dec 8;35(12 ):1211.

5.

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.

Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S, Gibson J, Wang J, Ljungström V, Wojdacz TK, Chaplin T, Roghanian A, Davis Z, Parker A, Tausch E, Ntoufa S, Ramos S, Robbe P, Alsolami R, Steele AJ, Packham G, Rodríguez-Vicente AE, Brown L, McNicholl F, Forconi F, Pettitt A, Hillmen P, Dyer M, Cragg MS, Chelala C, Oakes CC, Rosenquist R, Stamatopoulos K, Stilgenbauer S, Knight S, Schuh A, Oscier DG, Strefford JC.

Leukemia. 2016 Nov;30(11):2179-2186. doi: 10.1038/leu.2016.134. Epub 2016 May 20.

6.

Leukocyte Ig-Like receptor B1 restrains dendritic cell function through increased expression of the NF-κB regulator ABIN1/TNIP1.

Khanolkar RC, Kalogeropoulos M, Lawrie A, Roghanian A, Vickers MA, Young NT.

J Leukoc Biol. 2016 Oct;100(4):737-746. Epub 2016 Apr 29.

PMID:
27129285
7.

Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy.

Roghanian A, Cragg MS, Frendéus B.

Oncoimmunology. 2015 Aug 12;5(2):e1069939. eCollection 2016 Feb.

8.

B Cells Promote Pancreatic Tumorigenesis.

Roghanian A, Fraser C, Kleyman M, Chen J.

Cancer Discov. 2016 Mar;6(3):230-2. doi: 10.1158/2159-8290.CD-16-0100.

9.

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.

Tutt AL, James S, Laversin SA, Tipton TR, Ashton-Key M, French RR, Hussain K, Vaughan AT, Dou L, Earley A, Dahal LN, Lu C, Dunscombe M, Chan HT, Penfold CA, Kim JH, Potter EA, Mockridge CI, Roghanian A, Oldham RJ, Cox KL, Lim SH, Teige I, Frendéus B, Glennie MJ, Beers SA, Cragg MS.

J Immunol. 2015 Dec 1;195(11):5503-16. doi: 10.4049/jimmunol.1402988. Epub 2015 Oct 28.

10.

FcγR requirements leading to successful immunotherapy.

Dahal LN, Roghanian A, Beers SA, Cragg MS.

Immunol Rev. 2015 Nov;268(1):104-22. doi: 10.1111/imr.12342. Review.

PMID:
26497516
11.

Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendéus B, Cragg MS.

Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005.

12.

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.

Tipton TR, Roghanian A, Oldham RJ, Carter MJ, Cox KL, Mockridge CI, French RR, Dahal LN, Duriez PJ, Hargreaves PG, Cragg MS, Beers SA.

Blood. 2015 Mar 19;125(12):1901-9. doi: 10.1182/blood-2014-07-588376. Epub 2015 Jan 28.

13.

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.

White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, Potter EA, Ardern-Jones MR, Verbeek JS, Johnson PW, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ.

Cancer Cell. 2015 Jan 12;27(1):138-48. doi: 10.1016/j.ccell.2014.11.001. Epub 2014 Dec 11.

14.

Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412.

Hussain K, Hargreaves CE, Roghanian A, Oldham RJ, Chan HT, Mockridge CI, Chowdhury F, Frendéus B, Harper KS, Strefford JC, Cragg MS, Glennie MJ, Williams AP, French RR.

Blood. 2015 Jan 1;125(1):102-10. doi: 10.1182/blood-2014-08-593061. Epub 2014 Nov 13.

15.

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity.

Vaughan AT, Iriyama C, Beers SA, Chan CH, Lim SH, Williams EL, Shah V, Roghanian A, Frendéus B, Glennie MJ, Cragg MS.

Blood. 2014 Jan 30;123(5):669-77. doi: 10.1182/blood-2013-04-490821. Epub 2013 Nov 13.

16.

Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.

Williams EL, Tutt AL, Beers SA, French RR, Chan CH, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ.

J Immunol. 2013 Oct 15;191(8):4130-40. doi: 10.4049/jimmunol.1301430. Epub 2013 Sep 11.

17.

Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).

Williams EL, Tutt AL, French RR, Chan HT, Lau B, Penfold CA, Mockridge CI, Roghanian A, Cox KL, Verbeek JS, Glennie MJ, Cragg MS.

Eur J Immunol. 2012 Aug;42(8):2109-20. doi: 10.1002/eji.201142302. Epub 2012 Jul 4.

18.

WAP domain proteins as modulators of mucosal immunity.

Wilkinson TS, Roghanian A, Simpson AJ, Sallenave JM.

Biochem Soc Trans. 2011 Oct;39(5):1409-15. doi: 10.1042/BST0391409. Review.

PMID:
21936824
19.

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ.

J Immunol. 2011 Aug 15;187(4):1754-63. doi: 10.4049/jimmunol.1101135. Epub 2011 Jul 8.

20.

B cells--masters of the immunoverse.

Vaughan AT, Roghanian A, Cragg MS.

Int J Biochem Cell Biol. 2011 Mar;43(3):280-5. doi: 10.1016/j.biocel.2010.12.005. Epub 2010 Dec 13. Review.

PMID:
21147251
21.

Filament-associated TSGA10 protein is expressed in professional antigen presenting cells and interacts with vimentin.

Roghanian A, Jones DC, Pattisapu JV, Wolfe J, Young NT, Behnam B.

Cell Immunol. 2010;265(2):120-6. doi: 10.1016/j.cellimm.2010.07.012. Epub 2010 Aug 2.

PMID:
20797700
22.

Alternative mRNA splicing creates transcripts encoding soluble proteins from most LILR genes.

Jones DC, Roghanian A, Brown DP, Chang C, Allen RL, Trowsdale J, Young NT.

Eur J Immunol. 2009 Nov;39(11):3195-206. doi: 10.1002/eji.200839080.

23.

Neutrophil elastase (NE) and NE inhibitors: canonical and noncanonical functions in lung chronic inflammatory diseases (cystic fibrosis and chronic obstructive pulmonary disease).

Roghanian A, Sallenave JM.

J Aerosol Med Pulm Drug Deliv. 2008 Mar;21(1):125-44. doi: 10.1089/jamp.2007.0653. Review.

PMID:
18518838
24.

The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells.

Young NT, Waller EC, Patel R, Roghanian A, Austyn JM, Trowsdale J.

Blood. 2008 Mar 15;111(6):3090-6. Epub 2007 Dec 19.

25.

Inflammatory lung secretions inhibit dendritic cell maturation and function via neutrophil elastase.

Roghanian A, Drost EM, MacNee W, Howie SE, Sallenave JM.

Am J Respir Crit Care Med. 2006 Dec 1;174(11):1189-98. Epub 2006 Sep 7.

PMID:
16959917
26.

Human neutrophil elastase inhibitors in innate and adaptive immunity.

Fitch PM, Roghanian A, Howie SE, Sallenave JM.

Biochem Soc Trans. 2006 Apr;34(Pt 2):279-82. Review.

PMID:
16545094
27.

The antimicrobial/elastase inhibitor elafin regulates lung dendritic cells and adaptive immunity.

Roghanian A, Williams SE, Sheldrake TA, Brown TI, Oberheim K, Xing Z, Howie SE, Sallenave JM.

Am J Respir Cell Mol Biol. 2006 May;34(5):634-42. Epub 2006 Jan 19.

PMID:
16424380
28.

SLPI and elafin: one glove, many fingers.

Williams SE, Brown TI, Roghanian A, Sallenave JM.

Clin Sci (Lond). 2006 Jan;110(1):21-35. Review.

PMID:
16336202
29.

The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses.

McMichael JW, Roghanian A, Jiang L, Ramage R, Sallenave JM.

Am J Respir Cell Mol Biol. 2005 May;32(5):443-52. Epub 2005 Jan 24.

PMID:
15668324

Supplemental Content

Loading ...
Support Center